Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › cetuximab

cetuximab

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of cetuximab

178 trials tracked of cetuximab: 25 in phase 3 or 4 and 16 with published results. The most-cited published study has 2934 citations.

178Trials tracked
25Phase 3 & 4
0Recruiting
16With published results
Phase distribution
Phase 3 25 Phase 2 144 Phase 1 5 Other / NA 4
  1. Phase 3 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Completed · 2,934 cited
  2. Phase 3 Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Completed · 1,687 cited
  3. Phase 3 Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Completed · 1,289 cited
  4. Phase 3 Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed · 832 cited
  5. Phase 3 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Completed · 799 cited
  6. Phase 3 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed · 572 cited
Show 44 more trials
  1. Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Completed · 539 cited
  2. Phase 3 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Completed · 484 cited
  3. Phase 3 A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Completed · 257 cited
  4. Phase 3 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Completed · 207 cited
  5. Phase 3 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Completed · 64 cited
  6. Phase 3 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Completed · 64 cited
  7. Phase 3 Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer Completed · 61 cited
  8. Phase 3 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Completed · 53 cited
  9. Phase 3 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer Completed · 18 cited
  10. Phase 3 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Completed · 12 cited
  11. Phase 3 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed
  12. Phase 3 Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Completed
  13. Phase 3 ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed
  14. Phase 3 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer Completed
  15. Phase 3 Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer Completed
  16. Phase 3 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed
  17. Phase 3 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed
  18. Phase 3 Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) Completed
  19. Phase 3 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed
  20. Phase 2 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck Completed
  21. Phase 2 MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab Completed
  22. Phase 2 Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy Completed
  23. Phase 2 Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer Completed
  24. Phase 2 Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck Completed
  25. Phase 2 Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer Completed
  26. Phase 2 Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery Completed
  27. Phase 2 Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer Completed
  28. Phase 2 EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer Completed
  29. Phase 2 Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Completed
  30. Phase 2 Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer Completed
  31. Phase 2 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Completed
  32. Phase 2 Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors Completed
  33. Phase 2 Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed
  34. Phase 2 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Completed
  35. Phase 2 Palbociclib and Cetuximab in Metastatic Colorectal Cancer Completed
  36. Phase 2 A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Completed
  37. Phase 2 Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer Completed
  38. Phase 2 A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Completed
  39. Phase 2 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed
  40. Phase 2 A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Completed
  41. Phase 2 Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer Completed
  42. Phase 2 A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before Completed
  43. Phase 2 Preoperative Treatment With Cetuximab and/or IMC-A12 Completed
  44. Phase 2 Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed

Showing the 50 most-cited and recently-updated of 178 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Cetuximab maintenance therapy prolongs progression-free survival and overall survival versus observation in metastatic colorectal cancer
Drug Pipeline Meta-analysis
Cetuximab maintenance therapy prolongs progression-free survival and overall survival versus observation in metastatic colorectal cancer Cetuximab maintenance therapy extends survival in metastatic colorectal cancer
This systematic review and meta-analysis evaluated cetuximab maintenance therapy versus observation in metastatic colorectal cancer patients…
A new analysis finds that continuing cetuximab after initial treatment may help people with metastatic colorectal cancer live longer without…
Frontiers Jun 3, 2026
Avelumab plus cetuximab versus cetuximab alone in metastatic colorectal cancer patients
Gastroenterology RCT
Avelumab plus cetuximab versus cetuximab alone in metastatic colorectal cancer patients Adding avelumab to cetuximab helps only a specific subgroup of colorectal cancer patients
This randomized phase II trial evaluated adding avelumab to cetuximab in RAS/BRAF wild-type metastatic colorectal cancer patients.
A new trial shows adding avelumab to cetuximab improves survival only for patients without certain genetic changes, not for everyone.
May 1, 2026
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC
Oncology RCT
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC New Drug Order Doesn't Beat Old Standard
A phase III randomized controlled trial in 263 untreated, unresectable wild-type RAS/BRAF metastatic colorectal cancer patients found no dif…
A new drug order for advanced colon cancer did not improve disease control or survival compared to the standard treatment sequence.
Apr 16, 2026
Case report suggests grade 3 ICI-induced inflammatory arthritis may correlate with sustained response to tislelizumab in advanced head and neck carcinoma
Rheumatology Cohort
Case report suggests grade 3 ICI-induced inflammatory arthritis may correlate with sustained response to tislelizumab in advanced head and neck carcinoma Could a painful joint flare actually signal that cancer treatment is working long-term?
This case report and literature review describes a single patient with advanced unknown primary carcinoma of the head and neck receiving mai…
A patient with advanced head and neck cancer stayed in complete remission for over a year after joint pain from treatment forced doctors to …
Frontiers Apr 14, 2026
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab
ENT (Otolaryngology) Phase II
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab A Simple Blood Ratio May Predict Cancer Drug Success
This Phase II clinical trial evaluated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving combine…
A low white blood cell ratio found in blood tests predicts better survival and treatment response for advanced head and neck cancer patients…
Apr 13, 2026
Fulzerasib plus cetuximab shows 69% response in first-line KRAS-mutated NSCLC
Oncology Phase I
Fulzerasib plus cetuximab shows 69% response in first-line KRAS-mutated NSCLC Can a new drug combination shrink lung tumors in people with a specific KRAS mutation?
A single-arm phase 1b/2 trial in 47 treatment-naive patients with KRAS-mutated NSCLC found a confirmed objective response rate of 69% (90% C…
A new two-drug combination shrank tumors in nearly 70% of people with advanced lung cancer driven by a specific genetic mutation.
Apr 3, 2026
FDA Approves Krazati (adagrasib) for KRAS G12C-Mutated NSCLC and in Combination for Colorectal Cancer
Oncology FDA Approval
FDA Approves Krazati (adagrasib) for KRAS G12C-Mutated NSCLC and in Combination for Colorectal Cancer FDA approves a new targeted cancer drug called Krazati for lung and colorectal cancers
The FDA has approved Krazati as a single agent for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC after at least…
FDA approves Krazati, a new targeted drug for lung and colorectal cancers with a specific genetic change after other treatments fail.
FDA Mar 31, 2026